Catalent, Inc. (NYSE:CTLT) agreed to acquire Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million on August 9, 2022. Mayne Pharma will receive approximately $445 million in net proceeds after transaction costs, restructuring costs and customary closing adjustments. Catalent will pay the purchase price for this all-cash acquisition using a combination of cash on hand, existing credit facilities, and, depending on market conditions, potentially new debt financing. The closing of the acquisition is not contingent on any financing activity. The completion is subject to approval by antitrust authorities and is expected by end of calendar year 2022. Centerview Partners LLC acted as financial advisor to Mayne Pharma Group Limited. Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisor to Mayne Pharma Group Limited. Steven Epstein and Adam B. Cohen, Michael T. Gershberg, Bernard (Barry) A. Nigro Jr., Amy L. Blackman, Amir R. Ghavi, Peter L. Simmons, Michael J. Alter, Melissa A. Meyrowitz, Michael A. Kleinman, Donna Mussio and Nicole Tark of Fried, Frank, Harris, Shriver & Jacobson LLP acted as legal advisor to Catalent, Inc.

Catalent, Inc. (NYSE:CTLT) completed the acquisition of Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) on October 3, 2022. Following completion, Mayne Pharma will repay the syndicated debt facility and return a significant portion of excess funds to shareholders. Further details regarding the nature and timing of capital management initiatives (some of which will require shareholder approval at the 2022 Annual General Meeting on Wednesday 30th November) will be provided in the coming weeks.